No worries, it is common for e

Like
Comment
Favorite

No worries, it is common for extended duration for review especually for medical matters.

Humacyte Shares Tumble As FDA Review of Vascular Trauma Treatment Needs More Time

Humacyte shares fell 20% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.Shares were trading around $6.33. The stock has more than doubled in 2024.The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.

Humacyte Shares Tumble As FDA Review of Vascular Trauma Treatment Needs More Time

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":336754641174624,"tweetId":"336754641174624","gmtCreate":1723251575734,"gmtModify":1723251579594,"author":{"id":4088748055325860,"idStr":"4088748055325860","authorId":4088748055325860,"authorIdStr":"4088748055325860","name":"Kencom","avatar":"https://community-static.tradeup.com/news/bcaa9548fb78e0409a2827c590935dab","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":7,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.15","exceedPercentage":"80.21%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":92,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>No worries, it is common for extended duration for review especually for medical matters.&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>No worries, it is common for extended duration for review especually for medical matters.&nbsp;</p></body></html>","text":"No worries, it is common for extended duration for review especually for medical matters.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/336754641174624","repostId":2458542142,"repostType":2,"repost":{"id":"2458542142","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1723249752,"share":"https://www.laohu8.com/m/news/2458542142?lang=&edition=full","pubTime":"2024-08-10 08:29","market":"us","language":"en","title":"Humacyte Shares Tumble As FDA Review of Vascular Trauma Treatment Needs More Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2458542142","media":"Dow Jones","summary":"Humacyte shares fell 20% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.Shares were trading around $6.33. The stock has more than doubled in 2024.The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.","content":"<p>Humacyte shares fell 10% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/81d40f3e148819ca273f5ceac92b4556\" tg-width=\"411\" tg-height=\"381\"></p><p>Shares were trading around $6.33. The stock has more than doubled in 2024.</p><p>The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.</p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Humacyte Shares Tumble As FDA Review of Vascular Trauma Treatment Needs More Time</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHumacyte Shares Tumble As FDA Review of Vascular Trauma Treatment Needs More Time\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-08-10 08:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Humacyte shares fell 10% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/81d40f3e148819ca273f5ceac92b4556\" tg-width=\"411\" tg-height=\"381\"></p><p>Shares were trading around $6.33. The stock has more than doubled in 2024.</p><p>The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.</p><p></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4563":"昨日强势股","BK4139":"生物科技","HUMA":"Humacyte, Inc."},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2458542142","content_text":"Humacyte shares fell 10% in after-hours trading Friday after the Food and Drug Administration said it will require more time to review a proposed treatment for vascular trauma.Shares were trading around $6.33. The stock has more than doubled in 2024.The biotechnology company disclosed that the FDA will need more time to review a biologic license application for the acellular tissue engineered vessel in the vascular trauma indication. The acellular tissue engineered vessel trauma program application was submitted to the FDA in December.","news_type":1},"isVote":1,"tweetType":1,"viewCount":72,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":76,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}